GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease
Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site
A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases
NATCO’s Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alteration
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
Subscribe To Our Newsletter & Stay Updated